This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Spectrum Pharmaceuticals Elects Two New Healthcare Industry Veterans To The Board Of Directors

Spectrum Pharmaceuticals (NasdaqGS:SPPI), a biotechnology company with fully-integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the appointment of Dolatrai Vyas, Ph.D. and Raymond Cohen to its board of directors at the Annual Meeting of Stockholders held on June 28, 2013.

“I am pleased and honored to welcome two industry leaders to the Board of Directors,” said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals. “Dr. Vyas’ proven expertise in drug discovery and development and Mr. Cohen’s proven leadership in the healthcare industry will be instrumental as we continue to grow.”

Dr. Vyas spent more than 30 years in oncology drug discovery and research at Bristol-Myers Squibb Company (NYSE: BMY), a leading pharmaceutical company, most recently as a Group Director and Distinguished Research Fellow. During his tenure at BMY in oncology drug discovery, he participated in the discovery and development of 12 small molecules and one antibody drug conjugate as clinical development candidates with one US Food and Drug Administration approved NDA.

Mr. Cohen brings to the Board of Directors over 28 years of experience as an executive in the healthcare industry, including serving as Executive Chairman or Chief Executive Officer at several prominent companies. Until November 2012, Mr. Cohen served as Chief Executive Officer at privately-held Laguna Hills, CA-based Vessix Vascular Inc., a developer of a novel percutaneous RF balloon catheter renal denervation system used to treat uncontrolled hypertension. Vessix was acquired by Boston Scientific Corporation (NYSE: BSX) in November 2012 in a structured transaction valued at up to $425 million. Mr. Cohen is currently the Executive Chairman of JenaValve Technology, Inc., a venture backed company in the transcatheter aortic valve business, and among other board appointments chairs the Audit committee on the board of BioLife Solutions Inc. (OTC: BLFS), a manufacturer and marketer of preservation media for human cells and tissue.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,203.37 -85.26 -0.47%
S&P 500 2,107.78 -9.61 -0.45%
NASDAQ 4,979.9010 -28.1950 -0.56%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs